Aytu BioPharma, Inc. (AYTU) News
Follow Aytu BioPharma, Inc. (AYTU) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Rosemont to Acquire Aytu BioPharma in All-Cash Tender Offer
EQUITY | Nov 16, 2026, 09:11 PM UTC
L
Aytu BioPharma Is Maintained at Buy by Ascendiant Capital
Ratings actions from Benzinga: GMT) Aytu BioPharma Price Target Raised to $15.00/Share From $14.50 by Ascendiant CapitalRatings actions from Benzinga
NEWS | Sep 30, 2026, 10:06 AM UTC
L
Ascendiant Capital maintains Buy rating on Aytu BioPharma, $15 price target
Ascendiant Capital maintained their Buy rating on Aytu BioPharma's stock with a price target of $15.00.The price target implies an upside of 581.8% from the Sep 29 close of $2.20.Key takeaways from the analyst noteStrong
EARNINGS | Sep 30, 2026, 09:56 AM UTC
L
Weekly Recap: FY26 loss and Consumer Health sale, U.S. mfg move
Aytu BioPharma, Inc. (NASDAQ:AYTU) reported fiscal 2026 revenue of $57.57M and a $14.25M net loss while reshaping its business—selling Consumer Health, winding down non—core trials and shifting Adzenys/Cotempla manufactu
EARNINGS | Sep 28, 2026, 11:04 AM UTC
H
Transcript: Aytu BioPharma Q4 2026 Earnings Conference Call
On Tuesday, Aytu BioPharma (NASDAQ: AYTU ) discussed fourth-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you APIs. For real-time access to our e
LIVE | Sep 22, 2026, 09:16 PM UTC
M
Aytu BioPharma Q4 revenue beats estimates on EXXUA sales
EQUITY | Sep 22, 2026, 08:18 PM UTC
M
Aytu BioPharma reports FY2026 revenue $57.6M and Q4 $16.1M
FY2026 net revenue fell to $57.6M from $66.4M, while Q4 net revenue rose to $16.1M (+6.4% YoY). Fourth-quarter Adjusted EBITDA was $0.5M; full-year Adjusted EBITDA was a loss.
EQUITY | Sep 22, 2026, 08:14 PM UTC
L
AYTU - Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
AYTU - Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
EARNINGS | Sep 22, 2026, 08:05 PM UTC
L
AYTU - Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026
AYTU - Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026
EARNINGS | Sep 16, 2026, 08:30 PM UTC
M
AYTU Terminates Metadate Agreement
Aytu BioPharma terminates Metadate agreement with Lannett effective June 23, 2026
EQUITY | Jun 25, 2026, 08:40 PM UTC